Cathie Wood's ARKG biotech ETF rallies: Because nothing screams 'stable investment' like betting on CRISPR while the rest of tech pivots to survival mode

Cathie Wood's biotech-focused exchange-traded fund, ARKG, is experiencing a significant rally. As the founder and CEO of Ark Invest, Wood has been a prominent figure in the investment world, known for her bold and innovative approach to investing in cutting-edge technologies. The ARKG fund, which invests in companies involved in genomics and next-generation biotechnology, has been gaining momentum in recent weeks. With a portfolio that includes companies such as Crispr Therapeutics and Illumina, ARKG has been able to capitalize on the growing interest in biotech and genetic engineering. As of recent trading sessions, the fund has seen a notable increase in value, with investors flocking to the sector in anticipation of potential breakthroughs in medical research and treatment. The rally in ARKG is a testament to the growing significance of biotech in the investment landscape, with many experts predicting continued growth and innovation in the sector.